Chromosomal Microarray Analysis for the Fetuses with Aortic Arch Abnormalities and Normal Karyotype.

BACKGROUND: Aortic arch abnormalities (AAA) are abnormal embryologic developments of the aorta and its branches. Their outcomes often depend on their association with other congenital diseases and genetic testing results.
OBJECTIVE: This study aimed to evaluate the yield of chromosomal microarray analysis (CMA) in fetuses with different patterns of AAA and normal karyotype.
METHODS: Data from 158 pregnancies referred for prenatal CMA testing due to fetal AAA were obtained between April 2016 and April 2019. Fetuses with isolated AAA, AAA accompanied by soft ultrasound markers, and AAA with other ultrasound malformations were classified into groups A, B, and C, respectively. Cases with detectable karyotype aberrations were excluded from the study.
RESULTS: Twenty cases (12.7%) of submicroscopic anomalies were detected in 158 cases with normal karyotype, comprising 16 cases (10.1%) of clinically significant variants, two cases (1.3%) of variants of unknown significance, and two variants (1.3%) that were likely benign. Microdeletion of 22q11.2 accounted for 25% (4/16) of the clinically significant variants. The overall incremental yields by CMA in group A, group B, and group C were 1.8%, 2.3%, and 24.1%, respectively. Except for double aortic arch, the incremental yield of clinical significant findings for each type of AAA in group C was much higher than that in group A and group B. In group A, a clinically significant variant was only detected in one fetus with right aortic arch (RAA) (1.8%, 1/57).
CONCLUSIONS: In addition to 22q11.2 microdeletion, many other clinically significant submicroscopic variants are present in fetuses with AAA, especially in fetuses with other ultrasound malformations. Although CMA is always recommended in the presence of any malformation in many countries, our results suggest insufficient evidence to recommend CMA in fetuses with isolated AAA, except for isolated RAA.

Key Points

Introduction

Fetal aortic arch abnormalities (AAA) refer to position, length, and size abnormalities of the aortic arch and its branching vessels. These aberrations are the results of abnormal embryologic development of branchial arches, with a prevalence of approximately 1–3% [1, 2]. There are diverse patterns of aortic arch malformations. Common AAA patterns include right aortic arch (RAA), left aortic arch with aberrant right subclavian artery (LAA-ARSA), double aortic arch (DAA), coarctation of the aorta (CoA), and aortic arch interruption. They can occur in isolation or in association with cardiac defects and/or non-cardiac abnormalities [3, 4].

Many scholars have analyzed different patterns of AAA separately. Lodeweges et al. [5] analyzed an adult survival cohort with different types of congenital AAA, and provided the following information: most isolated AAA are asymptomatic and require no surgical therapy. Dyspnea was the most common syndrome associated with AAA, followed by gastrointestinal syndrome. They can be relieved by surgery; however, in prenatal settings, the premise is that there are no genetic abnormalities. Published studies on genetic testing for AAA have mainly focused on aberrant right subclavian artery (ARSA) and RAA. Their association with trisomy 21 (T21) as well as with 22q11 microdeletion detected by fluorescent in situ hybridization (FISH) has been reported frequently in both prenatal and postnatal settings [6-12]. Chromosomal microarray analysis (CMA) has become a front-line method for the genetic detection of fetal heart defects, because of its ability to detect both microscopic and submicroscopic chromosomal aberrations. It has been widely accepted for use in fetuses with AAA accompanied with cardiac anomalies or non-cardiac malformations, but its use in the management of cases with an isolated AAA remains controversial. For fetuses with ARSA as an isolated finding, an invasive procedure for CMA testing is not indicated, unless additional ultrasound abnormalities are detected [10, 13]. Some authors have recommended karyotyping and FISH for chromosome 22q11.2 microdeletion screening in all fetuses with RAA [3, 14]. The present study aimed to evaluate the implications of CMA in fetuses with various patterns of AAA with or without cardiac and/or non-cardiac malformations, and to provide incidence data for pregnancy guidance and fetal prognosis evaluation.

Materials and Methods

Patients and Samples

This retrospective study reviewed 204 consecutive pregnant women referred to our center because of fetal AAA accompanied with or without cardiac/non-cardiac malformations between August 2016 and May 2019. CMA was not performed in 30 cases. The other 174 cases underwent traditional karyotyping and CMA analysis concurrently, among whom, 16 cases with karyotype-detectable CMA findings were excluded from the study. As a result, 158 cases were enrolled in the study. The specimens included 112 cases with amniotic fluid obtained during 19 and 24 gestational weeks as well as 46 cases with umbilical cord blood obtained during 25 and 32 gestational weeks. The demographic characteristics are presented in Table 1. According to the ultrasound findings, the enrolled 158 patients were classified into three groups: isolated AAA (group A), AAA accompanied with soft ultrasound markers (group B), and AAA accompanied with other ultrasound malformations (group C). In group B, AAA with soft ultrasound markers was identified in 43 cases, and the most common soft ultrasound markers were echogenic intracardiac focus (34.9%, 15/43) and heart valve regurgitation (34.9%, 15/43). In group C, 58 fetuses had additional ultrasound malformations; among them, the most frequent cardiac anomaly was ventricular septal defect (VSD) (44.8%, 26/58), followed by persistent left superior vena cava (PLSVC) (17.2%, 10/58). The most frequent non-cardiac anomaly was fetal growth retardation (FGR) (13.8%, 8/58) (assigned when fetal weight, using the formula of Hadlock, was below the 10th percentile for gestational age), followed by urinary system anomalies (8.6%, 5/58) and skeletal system abnormalities (6.9%, 4/58).

Table 1

Demographic characteristics of the 158 enrolled pregnancies

	Total (n = 158)	Group A (n = 57)	Group B (n = 43)	Group C (n = 58)
Maternal age (years), mean ± SD	28.9 ± 4.0	28.4 ± 3.6	29.2 ± 3.4	29.1 ± 4.8
Gestation age at invasive testing (weeks), mean ± SD	24.6 ± 3.3	24.2 ± 3.3	25.2 ± 3.1	24.6 ± 3.5
Pregnancy outcomes
Ongoing/live born, n (%)	125 (79.1)	55 (96.5)	41 (95.3)	29 (50.0)
Still birth/TOP, n (%)	33 (20.9)	2 (3.5)	2 (4.7)	29 (50.0)

Group A = isolated AAA; group B = AAA accompanied with soft ultrasound markers; group C = AAA accompanied with other ultrasound malformations

AAA abnormal aortic arch, SD standard deviation, TOP termination of pregnancy

A clinical and ultrasound examination was suggested in surviving infants. Follow-up assessments were performed via clinical records or a telephone call, with the age of the infant at follow-up ranging from 5 to 24 months. The study was approved by the Ethics Committee of Fujian Provincial Maternity and Children’s Hospital. Written informed consent to participate in the study was obtained from each patient.

DNA Extraction and CMA Platforms

Genomic DNA was extracted from uncultured or cultured amniotic fluid and fetal cord blood using a QIAGEN kit (Qiagen, Germany) according to the manufacturer’s instructions. CMA was performed using a whole genome-wide Affymetrix CytoScan 750 K array (Affymetrix Inc., Santa Clara, CA, USA), which includes 200,000 probes for single nucleotide polymorphisms and 550,000 probes for copy number variations distributed across the entire human genome.

Data Interpretation

To analyze the results, Chromosome Analysis Suite software (Affymetrix) and human genome version GRCh37 (hg19) were used. A resolution was generally applied: gains or losses of ≥ 400 kb and loss of heterozygosity (LOH) ≥ 10 Mb. Uniparental disomy (UPD) was reported based on the identification of the region of homozygosity (ROH) covering the entire chromosome. UPDtool was used for genome-wide detection of UPD within the child–parent trios to confirm maternal or paternal UPD origin. All detected copy number variants (CNVs) were compared with in-house and national public CNV databases as follows: Database of Genomic Variants (DGV), Database of Chromosome Imbalance and Phenotype in Humans Using Ensemble Resources (DECIPHER), International Standards for Cytogenomic Arrays Consortium, and Online Mendelian Inheritance in Man (OMIM).

The incremental yield of CMA was defined as the yield of CMA over traditional karyotyping. The CMA results were classified into five levels according to the American College of Medical Genetics (ACMG) definitions [15]: pathogenic, benign, likely pathogenic, likely benign, and variants of unknown significance (VOUS). All of these results have been reported for patients. Submicroscopic (< 7 Mb) pathogenic/likely pathogenic CNVs were considered clinically significant. Parental CMA was recommended to determine the inheritance of CNVs. In general, CNVs inherited from normal phenotype parents were regarded as likely benign, whereas de novo fetal mutations were regarded as likely pathogenic. If the CNV had been reported to have incomplete penetrance and/or variable expressivity, we considered it a likely pathogenic variant, even though it was inherited from a parent with a normal phenotype.

Statistical Analysis

The data were analyzed using SPSS software v19.0 (SPSS Inc., Chicago, IL, USA). Statistical comparisons were performed using the Chi squared test, and p < 0.05 was considered statistically significant.

Results

Twenty cases (12.7%) of submicroscopic abnormalities were detected in the 158 cases with normal karyotype, and the details are summarized in Table 2. Among them, 1.3% (2/158) were variants of likely benign CNVs, 1.3% (2/158) were variants of VOUS, and 10.1% (16/158) were variants of clinical significance, which included nine cases of pathogenic CNVs, five cases of likely pathogenic CNVs, and two cases of UPD, as shown in Fig. 1. CNVs of clinical significance (n = 14) ranged in size from 507 kb to 7.4 Mb, and ten of them were related to clinical syndromes: DiGeorge syndrome (OMIM # 611867, cases 2, 3, 6, and 13), Potocki-Lupski syndrome (OMIM # 610883, cases 1 and 7), 1q21.1 duplication syndrome (OMIM # 612475, case 4), 8q21.11 deletion syndrome (OMIM # 614230, case 9), Williams-Beuren syndrome (OMIM # 194050, case 10), and 22q11.2 duplication syndrome (OMIM # 608363, case 14). Aberrations derived from 22q11.2, comprising four cases of deletion and one case of duplication, were observed with the highest frequency among the aberrations of clinical significance (25.0%, 4/16). In addition to CNVs of clinical significance, CMA yielded two cases of UPD from fetuses with AAA combined with intra- and non-cardiac abnormalities. Case 15 showed a maternal UPD (2) that affected the entirety of chromosome 2. Case 16 revealed a maternal UPD (16) involving 10.3 Mb and 19.2 Mb in regions 16q23.2q24.3 and 16p13.3p12.3, respectively. Of note, both fetuses manifested as FGR.

Table 2

Characteristic of submicroscopic variants detected from 20 fetuses with AAA and normal karyotype

Case number	Ultrasound findings (group)	CMA results	Size	Associated syndrome	Parental inheritance	Pathogenicity classification	Outcome
Variants of clinical significance
1	RAA with mirror-image branching (group A)	17p11.2 (16,615,982_18,922,171) × 3	2.3 Mb	Potocki-Lupski syndrome (# 610883)	De novo	Pathogenic	TOP
2	RAA-ALSA, VSD, U-shaped vascular rings (group C)	22q11.21 (18,648,855_21,800,471) × 1	3.1 Mb	DiGeorge syndrome (# 611867)	De novo	Pathogenic	TOP
3	RAA-ALSA, pulmonary atresia, VSD, PLSVC, thymus dysplasia, overriding aorta (group C)	22q11.21 (18,648,855_21,800,471) × 1	3.1 Mb	DiGeorge syndrome (# 611867)	De novo	Pathogenic	TOP
4	RAA, right ventricular stenosis, pulmonary stenosis (group C)	1q21.1q21.2 (145,995,176_147,398,268) × 3	1.4 Mb	1q21.1 duplication syndrome (# 612475)	–	Likely pathogenic	TOP
5	ARSA, echogenic intracardiac focus, mild tricuspid regurgitation (group B)	22q11.21 (18,919,477_21,800,471) × 1	2.8 Mb	DiGeorge syndrome (# 611867)	De novo	Pathogenic	TOP
6	ARSA, PLSVC, FGR (group C)	15q11.2 (22,770,421_23,277,436) × 1	507 Kb	None	De novo	Likely pathogenic	TOP
7	ARSA, strephenopodia (group C)	17p12p11.2 (15,759,453_20,547,625) × 3	4.7 Mb	Potocki-Lupski syndrome (# 610883)	De novo	Pathogenic	TOP
8	ARSA, VSD, PLSVC, Blake’s porch cyst (group C)	2q13 (111,397,196_113,111,856) × 1	1.7 Mb	None	Maternal	Likely pathogenic	Live born, normal development
9	CoA, VSD, increased spine curvature, FGR (group C)	5q22.3q23.1 (113,627,122_116,240,273) × 1	2.6 Mb	8q21.11 deletion syndrome (# 614230)	–	Pathogenic	Stillbirth
		8q21.11q21.13 (74,350,927_81,710,386) × 1	7.3 Mb
10	CoA, FGR (group C)	7q11.23 (72,713,282_74,154,209) × 1	1.4 Mb	Williams-Beuren syndrome (# 194050)	De novo	Pathogenic	TOP
11	CoA, hypoplastic left heart syndrome, VSD, PLSVC (group C)	8q23.1q23.2 (106,364,168_110,798,080) × 1	4.4 Mb	None	De novo	Pathogenic	TOP
12	CoA, VSD (group C)	18q23 (73,969,018_78,013,728) × 1	4.0 Mb	None	–	Pathogenic	TOP
		22q13.33 (49,571,996_51,197,766) × 3	1.6 Mb
13	CoA, interrupted aortic arch, VSD (group C)	22q11.21 (18,631,364_21,800,471) × 1	3.1 Mb	DiGeorge syndrome (# 611867)	De novo	Pathogenic	TOP
14	CoA, the oval valve bulges, small left heart (group C)	22q11.21 (18,649,189_21,800,471) × 3	3.1 Mb	22q11 duplication syndrome (# 608363)	De novo	Likely pathogenic	TOP
15	CoA, PLSVC, FGR (group C)	2p25.3p11.2 (50,813_87,053,152) hmz	87 Mb,	None	–	Pathogenic	Live born, normal development
		2q11.1q37.3 (95,550,957_242,773,583) hmz	147 Mb
16	CoA, VSD, renal dysplasia, FGR (group C)	16q23.2q24.3 (79,800,878_90,146,366) hmz	10.3 Mb	None	–	Pathogenic	TOP
		16p13.3p12.3 (94,807_19,302,326) hmz	19.2 Mb
Variants of non-clinical significance
17	RAA with mirror-image branching, VSD, overriding aorta, pulmonary stenosis (group C)	15q13.3 (32,003,537_32,444,043) × 3	441 kb	None	De novo	VOUS	TOP
18	ARSA, VSD, FGR (group C)	4q24 (106,284,925_107,545,257) × 3	1.3 Mb	None	De novo	VOUS	Premature birth, normal development
19	ARSA (group A)	7q34 (139,340,641_139,769,640) × 3	429 kb	None	Maternal	Likely benign	Live born, normal development
20	CoA, VSD (group C)	10q21.1 (59,095,330_60,684,488) × 1	1.5 Mb	None	Maternal	Likely benign	Live born, died after 20 days

AAA aortic arch abnormalities, ARSA aberrant right subclavian artery, CMA chromosomal microarray analysis, CoA coarctation of the aorta, FGR fetal growth restriction, PLSVC persistent left superior vena cava, RAA right aortic arch, RAA-ALSA right aortic arch with aberrant left subclavian artery, TOP termination of pregnancy, VOUS variants of unknown significance, VSD ventricular septal defect

Fig. 1

Flow chart illustrating the CMA findings of fetuses with AAA. AAA aortic arch abnormalities, CMA chromosomal microarray analysis, CoA coarctation of the aorta, LAA-ARSA left aortic arch with aberrant right subclavian artery, RAA right aortic arch, UPD uniparental disomy, VOUS variants of unknown significance

Of the enrolled 158 cases, the most frequent pattern was LAA-ARSA, accounting for 51.9% (82/158), followed by CoA (24.1%, 38/158), RAA (20.9%, 33/158), which included RAA with aberrant left subclavian artery (RAA-ALSA) as well as RAA with mirror-image branching, and DAA (3.16%, 5/158); their incremental yield of clinically significant findings was 4.9%, 21.1%, 12.1%, and 0%, respectively. Except for DAA, the incremental yield of clinical significant findings for each type of AAA in group C was much higher than that in group A and group B. A detailed summary is presented in Table 3. In group A, one out of 57 cases (1.8%) with isolated AAA yielded clinically significant results; the case was a fetus with RAA with mirror-image branching (Table 2, case 8). In group B, only one case of clinically significant findings was noted in a fetus with ARSA accompanied by echogenic cardiac focus and mild tricuspid regurgitation (Table 2, case 12), contributing to an incremental yield of 2.3%. In group C, 14 aberrations of clinical significance were identified, contributing to an incremental yield of 24.1%, comprising three cases of ARSA, three cases of RAA, and eight cases of CoA. It is worth noting that in group C, 35 patients had additional cardiac anomalies, ten cases had non-cardiac anomalies, and 13 cases had both non-cardiac and cardiac anomalies; their frequencies of clinically significant CMA findings showed no significant difference (17.1% vs. 20.0% vs. 46.2%, p > 0.05).

Table 3

Distribution of clinically significant CMA findings in fetus with normal karyotype

AAA pattern	Group A	Group B	Group C				Total
			Cardiac anomalies	Non-cardiac anomalies	Both cardiac and non-cardiac anomalies	Total in group C
Total	1.8%, 1/57	2.3%, 1/43	17.1%, 6/35	20.0%, 2/10	46.2%, 6/13	24.1%, 14/58	10.1%, 16/158
LAA-ARSA	0%, 0/35	3.1%, 1/32	0%, 0/6	25.0%, 1/4	40.0%, 2/5	20%, 3/15	4.9%, 4/82
RAAa	7.1%, 1/14	0%, 0/8	25.0%, 2/8	0%, 0/1	50.0%, 1/2	27.3%, 3/11	12.1%, 4/33
CoA	0%, 0/3	0%, 0/3	19.0%, 4/21	20.0%, 1/5	50.0%, 3/6	25.0%, 8/32	21.1%, 8/38
DAA	0%, 0/5	0%, 0	0%, 0	0%, 0	0%, 0	0%, 0	0%, 0/5

Group A = isolated AAA; group B = AAA accompanied with soft markers; group C = AAA accompanied with additional ultrasonic abnormalities

AAA abnormal aortic arch, CMA chromosomal microarray analysis, CoA coarctation of the aorta, DAA double aortic arch, LAA-ARSA left aortic arch with aberrant right subclavian artery, RAA right aortic arch

aIncluding RAA with aberrant left subclavian artery, RAA with mirror-image branching

Follow-up was obtained in 143 (90.5%) of our patients. Thirty-three fetuses were terminated or died in utero. All surviving infants had regularly visited a professional pediatrician. During the follow-up period, three cases with CoA and intracardiac malformations confirmed by postnatal echocardiography underwent cardiac surgery; one infant with ARSA as well as VSD showed developmental delay; one infant with isolated ARSA showed thyroid hypofunction; the rest of the cases showed no obvious phenotypic abnormality. Postnatal echocardiography was performed in only 38 cases; among them, prenatal diagnosis was confirmed in nine out of 13 fetuses (69.2%) with CoA, 13 out of 15 fetuses (86.7%) with RAA, two out of two cases (100%) with DAA, as well as seven out of eight cases (87.5%) with ARSA.

Discussion

The traditional classification of AAA was described by Crawford in 1964 [16]. In the present study, the enrolled cases mainly involved four common patterns: RAA, LAA-ARSA, CoA, and DAA.

The 22q11.2 microdeletion was considered to be the most relevant abnormality in previous studies on the correlation between various AAA and submicroscopic chromosomal abnormalities [17]. As isolated findings, the relationship is controversial [3, 8, 10–14, 18, 19]. In the current study, 22q11.2 was the most frequently affected region, with four cases of microdeletion and one case of microduplication. The 22q11.2 microdeletion accounted for 25% of fetuses with clinically significant submicroscopic chromosomal abnormalities. Among them, none was found in the isolated AAA group. One was found in the fetus with ARSA and a soft ultrasound marker (case 5); the fetus had echogenic cardiac focus and mild tricuspid regurgitation, and the pregnancy was terminated. The remaining three fetuses had additional cardiac anomalies. Some studies have suggested that the risk is significantly increased when the thymus is small or cannot be visualized and when extra-cardiac abnormalities are present [4, 19, 20]. In our study, only the fetus with 22q11.2 deletion detected in group C had thymus dysplasia, which was present in two cases of the whole cohort. Another variant that occurred with high frequency was 17p11.2 microduplication, which was present in two fetuses. One fetus with RAA with mirror-image branching was the only case of submicroscopic anomaly detected in group A (case 1). Another case was reported in a fetus with ARSA and strephenopodia (case 7). This aberration has not been reported in previous studies, especially for fetuses with isolated AAA. The duplication of 17q11.2 included the gene RAI1, whose overexpression has been linked to Potocki-Lupski syndrome (OMIM # 610883), resulting in various congenital abnormalities including developmental delays, autism, intellectual disability, cardiovascular anomalies, and certain other structural anomalies [21, 22]. Our findings suggest that, other than 22q11.2 microdeletion, more submicroscopic pathogenic aberrations may occur in isolated AAA.

The risk of genetic abnormalities increased when AAA was combined with cardiac and/or non-cardiac abnormalities. Pathogenic/likely pathogenic submicroscopic variants involved in clinical syndrome were also found in eight fetuses. As shown in Table 2, these fetuses all had additional cardiac anomalies except for case 10. Case 10 revealed Williams-Beuren syndrome, a well-defined multisystem disorder that is caused by a chromosome 7q11.23 deletion. As previously described, congenital cardiovascular defects are the most clinically significant in 80% of patients with Williams-Beuren syndrome, which is caused by haplo insufficiency in the elastin (ELN) [23, 24]. The ultrasound feature of case 10 was CoA and FGR, which was also reported in a study by Yuan et al. [25]. In their study, the researchers found that the most common ultrasound manifestations of William-Beuren syndrome in prenatal cases were FGR and congenital cardiovascular abnormalities mainly involving supravalvular aortic stenosis, VSD, or aortic coarctation. 1q21.1 duplication syndrome was detected in one fetus with RAA, right ventricular hypoplasia, and pulmonary stenosis (case 4). According to previous studies, 1q21.1 microduplication can be found in individuals with normal or abnormal phenotypes. Most patients were reported to be neurologically abnormal, mainly characterized by developmental delay, intellectual disabilities, or autism spectrum disorder [26, 27], contributing to 1q21.1 duplication syndrome; congenital heart defect was less commonly observed [28]. One fetus with CoA, VSD, increased spine curvature, and FGR revealed a 7.3-Mb deletion on 8q21.11, associated with 8q21 deletion syndrome. The syndrome is mainly characterized by intellectual disability and common facial dysmorphic features [29, 30], and congenital heart defects have also been rarely reported [31]. The fetus in our study died in utero at 34 gestational weeks, with no obvious abnormalities in the appearance of the delivered fetus.

Other rare variants of clinical significance, such as CNVs in the region of 2q13 and 18q23, have been reported to contribute to congenital heart disease [32-34]. The deletion of 2q13 encompasses the FBLN7 and TMEM87B genes, which account for cardiac defects; loss of FBLN7 may be responsible for impaired branchial arch development [33]. Although the deletion was inherited from the healthy parent, considering the incomplete penetrance and abnormal ultrasound features, the variant was classified as likely pathogenic, and the pregnancy was terminated. As for the deletion of 8q23.1q23.2 and 15q11.2 in this series, there are no previous studies about their association with congenital heart defects, and we considered them to be incidental findings. In addition, UPD was detected in two cases of CoA accompanied by cardiac anomalies and FGR. The pathogenesis of UPD is determined by both epigenetic imprinting and unmasking of autosomal-recessive diseases. Currently, two maternally expressed imprinted genes are located on chromosome 16: ZNF597 and NAA60. Fetuses with maternal UPD (16) were found in most cases to have FGR, and also in a few cases had malformations like cardiac defects [35, 36]. Similar to UPD (16), maternal UPD (2) was mainly reported in fetuses with FGR [37, 38], but fetal heart defects have not been reported previously, and they may also be an incidental finding.

Isolated ARSA is frequently considered to be benign and not associated with T21 or 22q11.2 deletion [18]. Some scholars have even concluded that CMA had no additive value in such cases, but a detailed ultrasound scan should be performed to further evaluate the risk of genetic abnormalities [10, 13]. But some scholars suggested that CMA should be considered in cases of prenatally diagnosed fetal cardiovascular malformations, even if the lesion is apparently isolated based on prenatal imaging [39]. Our findings are compatible with the former viewpoints. Compared to ARSA, the association of 22q11.2 microdeletion and RAA was more frequently documented. Some authors suggested that genetic testing, especially CMA, should be advocated regardless of co-existing malformations [8, 11, 12, 14, 19]. In previous studies, the incidence of clinically significant submicroscopic variants was variable. Ruan et al. reported an incidence of 5.2% in RAA fetuses with normal karyotype, all of which were 22q11.2 microdeletions [14]. In the study by Vigneswaran et al., an incidence of 8.6% was found in 69 apparently isolated RAA with normal karyotype, and the most common was a 22q11.2 microdeletion [40]. In our study, the incidence in isolated RAA fetuses and the total cohort was 7.7% and 12.5%, respectively. It is worth mentioning that various aberrations other than 22q11.2 microdeletion were present in our study, possibly because many additional ultrasound anomalies were also at high risk of genetic abnormalities. As far as we know, there have been few studies about the relationship between genetic abnormalities and fetal CoA, which may partly be because of insufficient accuracy for prenatal diagnosis of CoA, and its occurrence was always accompanied with other cardiac abnormalities. In our study, seven out of the 16 cases of clinically significant abnormalities were fetuses with CoA, accounting for the highest proportion. They all had additional ultrasound anomalies, and only 69.2% of the CoA cases who underwent postnatal echocardiography were confirmed. Therefore, the relationship between genetic abnormalities and CoA could not be assessed. In group C, most cases had both cardiac and non-cardiac anomalies, and the incidence of clinically significant submicroscopic variants was as high as 46.2%, which further emphasizes the importance of ultrasound screening for other systems when AAA is encountered.

Our study has several limitations. Firstly, it is a retrospective study and not all patients with AAA accepted CMA, especially the fetus with apparently isolated AAA. Secondly, not all fetal AAA were confirmed after birth or termination. Many parents were not willing to conduct echocardiography for their infants with no obvious symptom at early age. We should accept that, potentially, there may have been some misdiagnoses. Finally, the inability to detect single gene point mutations associated with AAA is a limitation of CMA; therefore, clinicians should be aware that karyotyping and CMA cannot find all the genetic aberrations.

In summary, our research suggests that CMA increases the diagnostic yield of clinically significant aberrations in fetuses with AAA compared to karyotyping, especially in fetuses with other ultrasound malformations. There was insufficient evidence to offer CMA in fetuses with isolated ARSA, CoA, and DAA, but it is advocated in isolated RAA and AAA accompanied with additional ultrasound abnormalities.

Chromosomal microarray analysis (CMA) increases the detection rate of clinically significant aberrations in fetuses with aortic arch abnormalities (AAA) compared with karyotyping.

It is of great importance to perform ultrasound screening for other systems when AAA is encountered.

There was insufficient evidence to offer CMA in fetuses with isolated aberrant right subclavian artery, coarctation of the aorta, and double aortic arch, but it is advocated in isolated right aortic arch and AAA accompanied with additional ultrasound abnormalities.